Background: The impact of pharmacist-led transition of care services with collaborative drug therapy management has shown to improve patients’ outcomes and decrease health costs. Compelling statistics show higher readmission rates for under-insured patients compared with insured patients at primary health care clinics. Methods: This is a single center, prospective, cohort study designed to examine team-based collaborative drug therapy management and its effect on therapeutic outcomes of under-insured patients with target chronic diseases managed in a primary health center. Targeted chronic diseases included dyslipidemia, diabetes, hypertension, anticoagulation disorders, chronic obstructive pulmonary disease, and heart failure. The primary outcome measures included percentage of time in therapeutic international normalized ratio (INR) and percentage of patients at targeted goals of blood pressure, lipids, and hemoglobin A1c (HbA1c). Secondary outcomes included reduced emergency department visits, number of patient encounters, hospital readmissions within 30 days of discharge, and disease exacerbation rates. Results: Patients were at INR goal 58% of the time compared with 52% at baseline ( P = .66). There was a 9% improvement in mean HbA1c in the intervention group when compared with baseline (9.6% vs 10.9%, P = .03). With pharmacist intervention, 73.8% of the patients had their blood pressure at goal compared with 50% at baseline ( P = .14). A limited number of patients were readmitted for different reasons, including uncontrolled disease states. Conclusions: The pharmacist-physician collaborative drug therapy management led to improved blood pressure control, average HbA1c, and time in therapeutic INR range. A decrease in health care utilization was also identified.

Purpose: The objective of this study is to determine the impact of a 48-hour time-out on the utilization of targeted empiric intravenous (IV) antibiotics through a systematic approach. Methods: This is a single-center, prospective, interventional study approved by the Institutional Review Board. Study groups were stratified into a control and intervention arm. Inclusion criteria consisted of patients 18 years of age or greater, on targeted broad-spectrum IV antibiotics for more than 24 hours: daptomycin, ertapenem, meropenem, piperacillin-tazobactam, vancomycin. Exclusion criteria included febrile neutropenic, pregnant, critically ill, and surgical prophylactic patients. Targeted interventions made by pharmacists included: IV to oral conversions, dose optimizations/adjustments, and de-escalations. Primary endpoints were days of therapy per 1000 patient days (DOT/1000), days of therapy at risk per 1000 patient days (DOT/1000 DAR), and de-escalation rates. Results: Table 1 depicts a total 88.69% mean reduction of DOT/1000 of the intervention arm for vancomycin, piperacillin/tazobactam, and meropenem ( P-value <.0001) when compared to the control arm. Table 2 depicts a total 88.86% mean reduction of DOT/1000 DAR of the intervention arm for vancomycin, piperacillin/tazobactam, and meropenem ( P-value <.0001) when compared to control. Table 3 shows a 77.11% increase in total de-escalation rates ( P-value = .0107) in the intervention group when compared to control group (63.52%). Conclusion: This study displays the essential role that pharmacists play in antibiotic stewardship. This study further reveals that the stewarding tool utilized contributed to significant reductions in the usage of targeted empiric intravenous antibiotics.